secwatch.observer — SEC 8-K summary
======================================

Issuer:     CDT Equity Inc. (CDT)
CIK:        0001896212
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001641172-25-022760
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Conduit renames to CDT Equity Inc., appoints James Bligh permanent CFO, adds 2M shares to incentive plan
--------------------------------------------------------------------------------

- Name change from Conduit Pharmaceuticals Inc. to CDT Equity Inc. effective Aug 5, 2025; ticker remains CDT; no shareholder vote required.
- James Bligh, co-founder and interim CFO since May 2024, appointed permanent CFO; compensation unchanged; retains board seat.
- Stockholders approved amendment to 2023 Stock Incentive Plan adding 2,000,000 authorized shares for awards.
- Press release details strategic shift: AI-driven drug repurposing via Sarborg partnership, animal health collaboration with Manoira, and evaluation of cryptocurrency treasury reserve strategy.
- All five director nominees elected: Andrew Regan, Freda Lewis-Hall, James Bligh, Chele Chiavacci Farley, Simon Fry; auditor CBIZ CPAs P.C. ratified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1896212/000164117225022760/0001641172-25-022760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1896212/000164117225022760/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-022760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer